GlassScriptPhysician profile
Richard Jay Shea
NPI 1578534004
$16,490.54
in general payments reported to CMS, 2019-2025
20 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $114 · 2021: $3,450 · 2022: $4,991 · 2023: $2,402 · 2024: $3,314 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,264 · Food and Beverage: $2,013 · Consulting Fee: $1,575 · Grant: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,263.86 |
| Food and Beverage | $2,013.07 |
| Consulting Fee | $1,575.00 |
| Grant | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $10,768.75 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Boston Scientific Corporation | $3,710.38 | 2019-2024 | Watchman Access System |
| Abbott Laboratories | $241.61 | 2021-2024 | Mitraclip, I-Stat |
| Medtronic Vascular, INC. | $188.99 | 2019 | |
| Amgen INC. | $180.81 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $162.12 | 2022-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $149.32 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $127.50 | 2023-2024 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $125.50 | 2024 | Inpefa |
| Medtronic, INC. | $123.98 | 2022 | |
| Amarin Pharma, INC. | $122.55 | 2023 | |
| Pfizer INC. | $119.27 | 2019-2025 | |
| Astellas Pharma US INC | $104.00 | 2022 | |
| Merck Sharp & Dohme LLC | $96.37 | 2023 | Verquvo |
| Novo Nordisk INC | $90.69 | 2024-2025 | Ozempic, Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $78.55 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $33.89 | 2023-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $33.75 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $18.80 | 2024 | Arcalyst |
| Biosense Webster, INC. | $13.71 | 2023 | Na |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Shea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.